Precision Biosciences (DTIL) FCF Margin (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly FCF Margin of 110.31% for Q1 2026, up 6580694.0% year-over-year from N/an in Q1 2025, and down 234.81% quarter-over-quarter from 32.95% in Q4 2025.
Precision Biosciences (DTIL) FCF Margin (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported FCF Margin for 9 consecutive years, with 110.31% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin rose 6580694.0% year-over-year to 110.31%; the TTM figure through Mar 2026 stood at 130.38% (down 1552.0% YoY), while the FY2025 annual figure was 192.41%, down 10697.0% from the prior year.
- FCF Margin declined to 110.31% in Q1 2026 per DTIL's latest filing, from 32.95% in the prior quarter.
- Across five years, FCF Margin topped out at 381.58% in Q3 2022 and bottomed at 117461.54% in Q3 2025.
- Historically, FCF Margin has averaged 17789.4% across 5 years, with a median of 212.07% in 2022.
- Annual changes were most pronounced in 2025 — FCF Margin plunged 11642838 bps — and 2026, when it jumped 6580694 bps.
- Precision Biosciences' FCF Margin stood at 212.07% in 2022, then soared by 44 bps to 119.31% in 2023, then plunged by 2367 bps to 2943.57% in 2024, then surged by 99 bps to 32.95% in 2025, then sank by 235 bps to 110.31% in 2026.
- Business Quant data shows DTIL's FCF Margin at 110.31% in Q1 2026, 32.95% in Q4 2025, and 117461.54% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.14 Bn | 132.29 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 87.02 Bn | 79.03 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 65.30 Bn | 60.12 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.84 Bn | 55.70 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 42.15 Bn | 37.06 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.49 Bn | 28.18 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 28.78 Bn | 10.38 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.14 Bn | 26.31 Bn | - | 70.82% |
| 10 | Precision Biosciences | 226.63 Mn | 139.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -110.31% |
| Dec 31, 2025 | -32.95% |
| Sep 30, 2025 | -117,461.54% |
| Jun 30, 2025 | -112,627.78% |
| Mar 31, 2025 | -65,917.24% |
| Dec 31, 2024 | -2,943.57% |
| Sep 30, 2024 | -1,033.16% |
| Jun 30, 2024 | -29.85% |
| Mar 31, 2024 | -108.43% |
| Dec 31, 2023 | -119.31% |
| Sep 30, 2023 | -178.96% |
| Jun 30, 2023 | -112.23% |
| Mar 31, 2023 | -364.29% |
| Dec 31, 2022 | -212.07% |
| Sep 30, 2022 | 381.58% |
| Jun 30, 2022 | -654.53% |
| Mar 31, 2022 | -895.09% |
| Dec 31, 2021 | -397.32% |
| Sep 30, 2021 | -102.50% |
| Jun 30, 2021 | -48.00% |